MRNA vs WDAY

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 19, 2026

MRNA

52.9
AI Score
VS
MRNA Wins

WDAY

48.1
AI Score

Investment Advisor Scores

MRNA

53score
Recommendation
HOLD

WDAY

48score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric MRNA WDAY Winner
Forward P/E 23.0415 17.2712 WDAY
PEG Ratio 0 0.6862 Tie
Revenue Growth 2.1% 12.8% WDAY
Earnings Growth -85.1% 206.0% WDAY
Tradestie Score 52.9/100 48.1/100 MRNA
Profit Margin -141.4% 12.3% WDAY
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

MRNA 1M: +40.0% · 3M: +156.6% WDAY 1M: -1.1% · 3M: +33.2%

Current Technical Phase

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (49.6% over 20 days), RSI 64

RSI (14): 63.6 · Price: $196.48

WDAY

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 45

RSI (14): 45.5 · Price: $184.26

Fundamentals Snapshot

Metric MRNA WDAY
Market Cap — —
Forward P/E -41.0 17.2
Trailing P/E — 38.0
Revenue (TTM) — —
Revenue Growth 0.0% 0.1%
Gross Margin -0.7% 0.8%
Operating Margin -5.6% 0.1%
EPS -7.36 4.91
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, MRNA is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.